(Q42211652)

English

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

scientific article published on 4 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 October 2017

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (English)

1 reference

Europe PubMed Central

18 October 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

interferon alfa

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

Sivi Ouwerkerk-Mahadevan

12

object named as

Sivi Ouwerkerk-Mahadevan

0 references

Maria Beumont-Mauviel

16

object named as

Maria Beumont-Mauviel

0 references

3

object named as

Fred Poordad

0 references

Patrick Marcellin

2

object named as

Patrick Marcellin

1 reference

Europe PubMed Central

18 October 2017

5

object named as

Maria Buti

1 reference

Europe PubMed Central

18 October 2017

7

object named as

Ewa Janczewska

1 reference

Europe PubMed Central

18 October 2017

author name string

Michael Manns

1

1 reference

Europe PubMed Central

18 October 2017

Evaldo Stanislau Affonso de Araujo

4

1 reference

Europe PubMed Central

18 October 2017

Yves Horsmans

6

1 reference

Europe PubMed Central

18 October 2017

Federico Villamil

8

1 reference

Europe PubMed Central

18 October 2017

Jane Scott

9

1 reference

Europe PubMed Central

18 October 2017

Monika Peeters

10

1 reference

Europe PubMed Central

18 October 2017

Oliver Lenz

11

1 reference

Europe PubMed Central

18 October 2017

Sivi Ouwerkerk-Mahadevan

12

1 reference

Europe PubMed Central

18 October 2017

Guy De La Rosa

13

1 reference

Europe PubMed Central

18 October 2017

Ronald Kalmeijer

14

1 reference

Europe PubMed Central

18 October 2017

Rekha Sinha

15

1 reference

Europe PubMed Central

18 October 2017

Maria Beumont-Mauviel

16

1 reference

Europe PubMed Central

18 October 2017

language of work or name

0 references

publication date

4 June 2014

1 reference

Europe PubMed Central

18 October 2017

1 reference

Europe PubMed Central

18 October 2017

384

1 reference

Europe PubMed Central

18 October 2017

414-426

1 reference

Europe PubMed Central

18 October 2017

9941

1 reference

Europe PubMed Central

18 October 2017

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel therapies for hepatitis C - one pill fits all?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New hepatitis C therapies: the toolbox, strategies, and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2960538-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)60538-9

1 reference

Europe PubMed Central

18 October 2017

1 reference

Europe PubMed Central

18 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42211652&oldid=1936016561"